EP4319827A1 - Marine scaffolds for human tissue generation - Google Patents
Marine scaffolds for human tissue generationInfo
- Publication number
- EP4319827A1 EP4319827A1 EP22721770.0A EP22721770A EP4319827A1 EP 4319827 A1 EP4319827 A1 EP 4319827A1 EP 22721770 A EP22721770 A EP 22721770A EP 4319827 A1 EP4319827 A1 EP 4319827A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tissue
- scaffold
- decellularized
- stem cells
- body part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001519 tissue Anatomy 0.000 claims abstract description 83
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 54
- 210000000130 stem cell Anatomy 0.000 claims abstract description 45
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 19
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 16
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 210000003205 muscle Anatomy 0.000 claims abstract description 7
- 210000000653 nervous system Anatomy 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 31
- 210000000845 cartilage Anatomy 0.000 claims description 16
- 241000258957 Asteroidea Species 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 11
- 239000012588 trypsin Substances 0.000 claims description 11
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 10
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 239000002738 chelating agent Substances 0.000 claims description 10
- 230000022159 cartilage development Effects 0.000 claims description 9
- 230000011164 ossification Effects 0.000 claims description 8
- 241000258955 Echinodermata Species 0.000 claims description 7
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims description 6
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims description 6
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 5
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 241000238421 Arthropoda Species 0.000 claims description 4
- 241001441986 Clypeasteroida Species 0.000 claims description 4
- 241000243321 Cnidaria Species 0.000 claims description 4
- 241000257465 Echinoidea Species 0.000 claims description 4
- 241000251511 Holothuroidea Species 0.000 claims description 4
- 241000234435 Lilium Species 0.000 claims description 4
- 241000237852 Mollusca Species 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000010146 3D printing Methods 0.000 claims description 3
- -1 ECM Proteins 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- PQHYOGIRXOKOEJ-UHFFFAOYSA-N 2-(1,2-dicarboxyethylamino)butanedioic acid Chemical compound OC(=O)CC(C(O)=O)NC(C(O)=O)CC(O)=O PQHYOGIRXOKOEJ-UHFFFAOYSA-N 0.000 description 4
- CIEZZGWIJBXOTE-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]propanoic acid Chemical compound OC(=O)C(C)N(CC(O)=O)CC(O)=O CIEZZGWIJBXOTE-UHFFFAOYSA-N 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 2
- VCVKIIDXVWEWSZ-YFKPBYRVSA-N (2s)-2-[bis(carboxymethyl)amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)N(CC(O)=O)CC(O)=O VCVKIIDXVWEWSZ-YFKPBYRVSA-N 0.000 description 2
- PWVRXSQPCQPQHM-UHFFFAOYSA-N 2-(4-aminophenyl)-1h-indol-6-amine Chemical compound C1=CC(N)=CC=C1C1=CC2=CC=C(N)C=C2N1 PWVRXSQPCQPQHM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 2
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102100022375 Dentin matrix acidic phosphoprotein 1 Human genes 0.000 description 1
- 101710105839 Dentin matrix acidic phosphoprotein 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001670157 Gymnura Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710108470 Hyalin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 102000011723 Matrix Metalloproteinase 11 Human genes 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 102000011722 Matrix Metalloproteinase 13 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Definitions
- the present inventive concept relates to the field of marine scaffold matrices for generation of personalized tissues for future clinical application. More particularly, the inventive concept relates to a method for generation and evaluation of personalized human grafts using decellularized marine invertebrates as novel bio-scaffolds recellularized with patient’s autologous stem cells.
- BACKGROUND Osteoarthritis is a degenerative joint disease that affects millions of people worldwide.
- the disease is characterized by progressive loss of hyaline cartilage in the synovial joints which leads to significant joint pain, swelling and stiffness for sufferers.
- the disease is also a significant economic burden.
- the current gold standard treatment option for OA is total joint arthroplasty where the diseased cartilage and underlying bone are replaced with a metal and polymer prosthesis. While the procedure is well established failures and complications are not uncommon. For tissues such as cartilage the need for new approaches is large since the body’s own capability to produce and heal cartilaginous tissue is poor.
- Bone is well known for its self-healing abilities. Nevertheless, in pathological fractures or large and massive bone defects, bone healing and repair fail. Major bone reconstruction procedures often use autografts, allografts, or xenografts to improve bone healing, but these have their disadvantages and limitations. Advances in tissue engineering have facilitated the development of replacement tissues or organs for the treatment of injured or degenerative tissue. Scaffolds represent important components for tissue engineering.
- One group of biological scaffold materials that are already commonly in use for a variety of reconstructive surgical applications is that derived from the extracellular matrix (ECM). Such scaffolds are produced by the process of decellularization of tissue/organs.
- ECM derived from decellularization of various organs and tissues such as liver, bladder, blood vessel, lung, bone, etc has shown promising results in creating a biological scaffold capable of providing a favourable environment for survival, proliferation, and differentiation of the resident cells (stem cells/primary cells).
- WO201 2/058617 discloses a method for forming a bone tissue module comprising inducing different progenitor cells to form osteogenic progenitor cells, expanding the osteogenic progenitor cells, combining the osteogenic progenitor cells and a scaffold, i.e. decellularized bone and incubating the osteogenic progenitor cells and the scaffold, seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
- WO94/03584 discloses a method of producing graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells i.e. a marine animal connective tissues or produced from extracellular matrix proteins; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth to form a processed connective tissue source; and c) fragmenting the processed connective tissue source to produce connective tissue particulates, thereby producing graft tissue, seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
- the product obtained by this method is suitable for 3D-printing but is less suitable for direct use since the connective tissue is fragmented into particulates.
- CN1 10193096 discloses a marine-derived biomimetic cartilage material and a preparation method thereof.
- the marine-derived cartilage may derive from fish cartilage, shark cartilage, stingray cartilage, mackerel cartilage, squid cartilage, etc.
- the method comprises the steps of decellularizing the cartilage for direct use in human bodies.
- the method specifically makes use of cartilage which means the cartilage must be isolated from the remaining part of the marine subject prior to decellularization.
- Another problem lies in that the product obtained is not adapted for humans and therefore it takes time for the human body to accept it as graft since no human cells are introduced.
- An object of the disclosure is to provide a method for generation of personalized tissue-engineered human grafts for direct use.
- a method for generation of personalized tissue-engineered human grafts comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, the body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing the body part with distilled water; c) decellularizing the washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix (ECM) proteins, and, optionally, d) recellularizing the decellularized 3D-scaffold by: inoculating human stem cells into the decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in
- the method provides the advantage that the starting material comprises tissue that is maintained in its natural environment, i.e. the tissues are not separated from each other.
- a method for generation of personalized tissue-engineered human grafts for direct use comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, the body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing the body part with distilled water; c) decellularizing the washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix (ECM) proteins, and, d) recellularizing the decellularized 3D-scaffold by: inoculating human stem cells into said decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in vitro culturing said human stem cells in said inoculated 3D-scaffold.
- ECM extracellular matrix
- Marine invertebrates Many marine invertebrates have capacity to regenerate their internal and exterior organs and thus constitute suitable scaffolds for tissue engineering. Furthermore, many marine invertebrates possess ECM proteins that are immunologically related to known ECM proteins found in vertebrates, e.g. fibronectin, laminin, fibrillar collagen which has strong similarities with collagen type I, and glycosaminoglycans which belongs to the sulphate family. They also may possess a hyalin layer, an apical lamina, and the basal lamina which is beneficial since it provides a more complex and robust structure. Furthermore, several matrix metalloproteinases and tissue inhibitors of metalloproteinases have been found in marine invertebrates. Marine invertebrates thus constitute a prominent and sustainable source for scaffolds for tissue engineering.
- the marine invertebrate is selected from Echinoderms, Poriferans, Cnidarians, Mollusks, or Arthropods; preferably wherein the marine invertebrate is selected from Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies.
- Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies.
- poriferans are sponges
- Cnidarians are sea Jellies and Corals
- Mollusks are octopuses
- snails snails
- clams and of Arthropods are insects, spiders, and lobsters.
- the body part derived from echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, and sea lilies.
- Starfish is advantageous since it is possible to derive large body parts therefrom and it contains large amounts of soft tissue and muscle which is easier to recellularize than bony tissue.
- the body part derives from Echinoderms, Poriferans, Cnidarians, Mollusks, or Arthropods; or wherein the body part derive from Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies.
- the body part is large enough to produce reasonable amounts of tissue engineered human grafts. Naturally, the larger the body part the more tissue engineered human graft may be obtained.
- the body part may be at least 5 cm in length, such as at least 10 cm, and preferably at least 20 cm in length.
- the method further comprises a step of decalcifying the washed body part obtained in step b) before the step c).
- Decalcification describes a technique for removing calcium ions and/or other mineral from bone or other calcified tissues in order to soften. Decalcification is thus advantageous in cases of bony and/or hard tissue structures. It is easier to recellularize a decalcified tissue than a non-decalcified tissue since the decalcification makes the tissue softer, especially if the tissue originally comprises substantial amounts of bone.
- the step of decalcification is employed by a decalcification media comprising an acid, such as hydrochloric acid, nitric acid, and formic acid.
- a decalcification media comprising an acid, such as hydrochloric acid, nitric acid, and formic acid.
- the step of decalcification is employed by a decalcification media comprising an acid and a chelating agent.
- the step of decalcification is employed by a decalcification media comprising a chelating agent.
- chelating agents are ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), iminodisuccinic acid (IDS), polyaspartic acid, S,S-ethylenediamine- N,N'-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), L-Glutamic acid N,N-diacetic acid, and tetrasodium salt (GLDA).
- EDTA ethylenediaminetetraacetic acid
- NDA nitrilotriacetic acid
- IDS iminodisuccinic acid
- MGDA methylglycinediacetic acid
- MGDA methylglycinediacetic acid
- the tissue is shaken during the step of decalcification.
- the time for shaking may be 2-4 hours.
- the decalcification is employed at room temperature. Decellularization
- Decellularization refers to a process of removal of substantially all cellular components in the tissue.
- the resulting decellularized 3D-scaffold is substantially depleted of cellular cytoplasmic and nuclear material.
- the decellularized 3D-scaffold may be described as substantially immunologically inert.
- Decellularization may be employed by physical means and/or decellularization media such as detergents, salts, and enzymes. It is an advantage if the decellularization results in a decellularized 3D-scaffold which is kept as intact and natural as possible. Hereby, recellularization is easier and it is also easier to integrate the human graft in the human body.
- the decellularization may result in a decellularized 3D-scaffold which comprises muscle, collagen, GAG, signal peptides, and/or growth factors. For this reason, it is advantageous to use soft decellularization media.
- the decellularized 3D-scaffold has a concentration of DNA of less than 20 ng dsDNA/mg body part (dry weight). In one example embodiment, the decellularized 3D-scaffold has a fragment length of the DNA of less than 200 bp.
- the decellularization media comprises trypsin.
- Trypsin which is a commonly used enzyme for tissue decellularization, is classified as a soft decellularization media.
- concentration of trypsin may be from 0.01 wt% to 1 wt%, such as from 0.05 wt% to 0. 075 wt%.
- the step c) comprises addition of a decellularization media comprising trypsin and a chelating agent.
- a decellularization media comprising trypsin and a chelating agent.
- concentration of trypsin may be between 0.01 wt% to 1 wt%, such as 0.05 wt% to 0. 75 wt%.
- concentration of chelating agent may be from 0.1 mM to 20 mM, such as 5 mM to 10 mM.
- Non-limiting examples of chelating agents are ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), iminodisuccinic acid (IDS), polyaspartic acid, S,S-ethylenediamine-N,N'-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), L-Glutamic acid N,N-diacetic acid, and tetrasodium salt (GLDA).
- EDTA ethylenediaminetetraacetic acid
- NDA nitrilotriacetic acid
- IDDS iminodisuccinic acid
- EDDS polyaspartic acid
- S,S-ethylenediamine-N,N'-disuccinic acid methylglycinediacetic acid
- MGDA methylglycinediacetic acid
- L-Glutamic acid N,N-diacetic acid and tetrasodium
- the decellularization media comprises trypsin and ethylenediaminetetraacetic acid (EDTA).
- EDTA is often used with trypsin, an enzyme that acts as a protease to cleave the already existing bonds between integral proteins of neighboring cells within a tissue.
- trypsin an enzyme that acts as a protease to cleave the already existing bonds between integral proteins of neighboring cells within a tissue.
- the EDTA-Trypsin combination is efficient for decellularizing decalcified tissues.
- SDS sodium dodecyl sulfate
- residual SDS is difficult to completely remove and may lead to an undesirable host response towards an implanted biomaterial.
- SDS is classified as a harsh detergent which is effective in cell elimination but causes disturbance of the ECM structure and denaturation of the ECM proteins.
- SDS may also cause removal of non-fibrillar elements, such as reduced GAGs and growth factor content, as well as denaturation of collagen.
- preservation of non-fibrillar elements such as GAG and proteoglycans is advantageous since they play an important role in cell-cell interaction, cell adhesion, survival, migration, proliferation, and maintaining the 3D structure and hydration level of the tissue.
- the decellularization media may be a non-SDS based decellularization media.
- the decellularization may for example be performed by a decellularization media which comprises no more than 2 wt% SDS, no more than 1 wt% SDS, and preferably no SDS.
- decellularization media which contains SDS, or is SDS-based, may cause loss in mechanical properties of the ECM structure, resulting in a decellularized scaffold without 3D-structure.
- decellularized scaffold typically contains only collagen and negligible amounts of GAGs.
- a way to overcome this problem is to crosslink the ECM structure, i.e. the collagen.
- HCI hydrochloric acid
- NaOH sodium hydroxide
- the decellularization may for example be performed by a decellularization media which comprises no more than 1 wt% HCI, no more than 0.5 wt%, and preferably no HCI.
- the decellularization may for example be performed by a decellularization media which comprises no more than 0.5 wt% NaOH, and preferably no NaOH.
- the method is performed without crosslinking, i.e. the method may result in a non-crosslinked decellularized 3D- scaffold.
- the decellularized 3D-scaffold may be a non- crosslinked decellularized 3D-scaffold.
- the method may not contain a step of bleaching.
- the step c) comprises addition of a decellularization media comprising matrix metalloproteinases (MMP) and a chelating agent.
- MMP matrix metalloproteinases
- Non-limiting examples of activated matrix metalloproteinases are MMP1 , MMP2, MMP3, MMP7, MMP8, MMP9, MMP11, MMP13, and Membrane type 1 -matrix metalloproteinase (MT1-MMP).
- the concentration of the MMP may be in the interval of 1-10 pg/ml and preferably 2-5 pg/ml.
- Activated MMPs may be in the interval from 0.5 pg/ml to 10 pg/ml, such as 1.0 pg/ml to 5 pg/ml.
- Metalloproteinases are metalloproteinases that are calcium-dependent zinc- containing endopeptidases. Collectively, these enzymes are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands. MMPs are also thought to play a major role in cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense.
- the step of decellularizing is performed in a temperature range of 15-37°C.
- the method further comprises a step of conditioning the decellularized 3D-scaffold.
- Conditioning may be employed by MMP-inhibitor such as hydroxymates and/or chelating agent such as carboxylates, thiols, and phosphinyls. Hydroxymates are particularly potent inhibitors of MMPs and other zinc-dependent enzymes, due to their bidentate chelation of the zinc atom.
- the method further comprises a step of freezing the decellularized 3D-scaffold obtained in step c).
- the decellularized 3D-scaffold is frozen and thawed before the step of recellularizing.
- the step of decellularization is preferably employed to a fresh body part, i.e. a body part that has not been frozen. The reason for that is that tissue, particularly tissue proteins, may be destroyed if frozen repeatedly.
- the human stem cells are isolated from at least one of human bone marrow, blood, and adipose. Stem cells isolated from blood is advantageous since it does not require any surgical operation to collect.
- said stem cells comprise mesenchymal stem cells (MSC).
- MSCs mesenchymal stem cells
- stromal cells also known as mesenchymal stromal cells or medicinal signaling cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).
- said human stem cells comprise enriched stem cells such as CD271 and/or CD90 expressing cells.
- CD271 and CD90 are markers used to identify i.e. mesenchymal stem cells from diverse sources.
- the official full name of CD271 is nerve growth factor receptor (TNFR superfamily, member 16).
- CD271 also called the LNGFR or p75 neurotrophin receptor, regulates neuronal growth, migration, differentiation, and cell death during stem cells. It is one of the two receptor types for the neurotrophins, a family of protein growth factors that stimulate neuronal cells to survive and differentiate.
- LNGFR is a member of the tumor necrosis factor receptor (TNF receptor) superfamily.
- the official full name of CD90 is Thy-1 cell surface antigen.
- This gene encodes a cell surface glycoprotein and member of the immunoglobulin superfamily of proteins.
- the encoded protein is involved in cell adhesion and cell communication in numerous cell types, but particularly in cells of the immune and nervous systems.
- the encoded protein is widely used as a marker for hematopoietic stem cells.
- the human stem cells comprise unexpanded and undifferentiated human stem cells.
- the human stem cells may then differentiate in the recellularized 3D-scaffold to chondrocytes and/or osteocytes.
- Chondrocytes are the only cells found in healthy cartilage. They produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans.
- An osteocyte is an oblate shaped type of bone cell with dendritic processes and is the most commonly found cell in mature bone tissue.
- a growth factor is inoculated together with the human stem cells into the decellularized 3D-scaffold
- the growth factor comprises chondrogenesis media and/or osteogenesis media.
- a growth factor is inoculated together with the human stem cells into said decellularized 3D-scaffold and wherein the growth factor comprises chondrogenesis media and/or osteogenesis media.
- chondrogenesis medium and their concentrations include: MEM with alpha modification, 1% Penicillin & Streptomycin, 10% inactivated AB serum, 1% L-glutamine, TGF Beta 3 (10 ng/ml), Bone morphogenetic protein-2 (10 ng/ml), Bone morphogenetic protein-4 (10 ng/ml), Basic Fibroblast growth factor (10 ng/ml), Epidermal growth factor (1 ng/ml), Insulin-like growth factor (5 ug/ml), Transferrin (5 ug/ml), Sodium-Selenite (5 ug/ml), Proline (0.35 mM), Ascorbic acid-2-phosphate (0.17 mM) or L- Ascorbic acid (50 ug/ml), and Dexamethasone (
- Non-limiting examples of Osteogenesis medium and their concentrations include: Minimum essential medium (MEM) (High glucose), Penicillin & Streptomycin, 10% inactivated AB serum, 1 % L-glutamine, L-Ascorbic acid (1 mM), Beta-Glycerophosphate (10 mM), and Dexamethasone (10 nM).
- MEM Minimum essential medium
- Penicillin & Streptomycin 10% inactivated AB serum
- 1 % L-glutamine 1 % L-glutamine
- L-Ascorbic acid 1 %
- Beta-Glycerophosphate 10 mM
- Dexamethasone 10 nM
- Cell attachment to a scaffold is a significant step toward successful tissue engineering.
- Cell inoculation is the first stage of cell attachment, and its efficiency and distribution can affect the final biological performance of the scaffold.
- Efficiency in this context may be defined as seeding efficiency of at least 40% of seeded cells as determined by the quantity of cellular DNA within 5 hours after seeding.
- Distribution in this context may be defined as percentage of area occupied by cells in tissue as enumerated and quantified by histology.
- the cells may be inoculated by seeding, such as by injection or perfusion.
- the step d) further comprises centrifugating the inoculated 3D-scaffold. Centrifugation is advantageous since it may improve cell distribution within the body part. Centrifugation may also decrease the time for cell attachment. The centrifugation may be performed during at least 1 minute, at least 3 minutes or at least 5 minutes.
- At least 0.1 million cells/mm 2 , at least 0.2 million cells/mm 2 , at least 0.3 million cells /mm 2 , at least 0.4 million cells/mm 2 , or at least 0.5 million cells/mm 2 are seeded to the decellularized 3D-scaffold.
- 1 million cells/mm 2 are inoculated to the decellularized 3D-scaffold.
- the cells may be inoculated all at the same time or portion-wise in intervals.
- the cells may be inoculated on top of the decellularized 3D-scaffold.
- the inoculated decellularized 3D-scaffold is centrifugated directly after inoculation. In one example embodiment, the inoculated 3D-scaffold is centrifugated at least 5 min, at least 15 min, at least 30 min, at least 45 min or at least 60 min after seeding.
- the step of recellularizing further comprises culturing of cells in a bioreactor for 1-8 weeks, and preferably 2-4 weeks.
- culturing of cells in a bioreactor for 1-8 weeks, and preferably 2-4 weeks.
- tissue-engineered human graft as herein described is provided.
- the tissue-engineered human graft may express human genes.
- the detection of human genes may be performed by Real-Time polymerase chain reaction (PCR), microarray or by Proteomics.
- the graft comprises soft bone and/or cartilage.
- Soft bone is also called cancellous trabecular or spongy bone. It consists of a network of trabeculae or rod-like structures. It is lighter, less dense, and more flexible than compact bone.
- Soft bone is a very porous type of bone found in animals. It is highly vascularized and contains red bone marrow. Soft bone is usually located at the ends of the long bones, with the harder compact bone surrounding it. It is also found inside the vertebrae, in the ribs, in the skull and in the bones of the joints. Soft bone is softer and weaker than compact bone but is also more flexible.
- Compact (cortical) bone is a hard outer layer that is dense, strong, and durable. It makes up around 80 percent of adult bone mass.
- the tissue-engineered human graft as herein described comprises soft bone, cartilage, and/or skin.
- Further examples of tissue-engineered human grafts obtainable by the invention are skin and blood vessels.
- tissue engineered human graft for use in therapy is provided.
- a tissue engineered human graft for treatment of Osteoarthritis is provided.
- a tissue engineered human graft for treatment of joint diseases is provided.
- joint diseases are Osteoarthritis, Post-traumatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Osteoporosis, Discoid meniscus, Bone disorders such as Bone Cancer, Bone Density, Bone Infections, Osteogenesis Imperfecta, Osteonecrosis, Osteoporosis, Paget's Disease of Bone, and Rickets.
- a tissue engineered human graft as herein described may be used as ink for 3D printing.
- the ink is provided with good mechanical properties. It is an advantage if the ink comprises muscle because this gives stiffness to the printed material. Collagen, GAGs, signal peptides, and/or growth factors further enhance stiffness and allow the cells to adhere to the ink in an efficient way.
- the ink may comprise polysaccharides such as mannoglucan sulfate, P1 and P2 which act as antioxidants and enhance cell adhesion, migration, and differentiation.
- the ink exhibits good printability and mechanical properties needed for 3D microgeometry integrity and required cellular functions such as viability and differentiation. Definitions
- Recellularization refers to the process of delivering cells to a decellularized 3D- scaffold and culturing the cells such that the cells proliferate and differentiate to generate a personalized tissue-engineered human graft.
- Decalcification describes the technique for removing calcium ions and/or other mineral from bone or other calcified tissues to soften.
- Inoculation refers to the spread of cells to a tissue or body part for cell culture activities.
- FIG. 1 illustrates a flow chart for a method for generation of personalized tissue- engineered human grafts for direct use according to at least one example embodiment of the inventive concept
- Fig. 2a illustrates a flow chart for a method for recellularization of a decellularized 3D-scaffold according to at least one example embodiment of the inventive concept
- Fig. 2b illustrates a flow chart for a method for recellularization of a decellularized 3D-scaffold
- Fig. 3a and 3b illustrate a comparison of an inoculated 3D-scaffold without centrifugation and an inoculated 3D-scaffold with centrifugation.
- Fig. 1 illustrates a flow chart for a method for generation of personalized tissue- engineered human grafts for direct use.
- a body part taken from marine invertebrates is collected and washed with distilled water to remove debris. Possibly the body part is maintained in flowing sea water until needed.
- the body part is preferably decalcified in order to make it softer.
- decalcification media are hydrochloric acid, nitric acid, formic acid, and ethylenediaminetetraacetic acid (EDTA).
- the body part is subjected to stirring during decalcifying. The time for decalcification may be two hours and the temperature may be room temperature. Subsequently the decalcified body part is preferably repeatedly washed with distilled water.
- the body part is decellularized into a decellularized 3D-scaffold which means substantially all cells and DNA are removed.
- Decellularization is preferably also performed during stirring.
- the time for decellularization may be two hours and the temperature may be 37 ° C.
- Non-limiting examples of decellularization media are trypsin-EDTA.
- the outcome of decalcification and decellularization processes may be analyzed by histology.
- the decellularized 3D-scaffold may now be frozen until later use. Hereby, an off-the-shell product is produced.
- the decellularized 3D-scaffold Before the decellularized 3D-scaffold is recellularized, it is preferably is sterilized and conditioned. Sterilization may be performed by subjecting the 3D- scaffold to peracetic acid in sterile phosphate-buffered saline (PBS) for 1 hour on a shaker at room temperature. Bony tissue may be washed with sterile PBS three times, each time for 20 minutes.
- PBS sterile phosphate-buffered saline
- Recellularization is performed by inoculating, such as seeding, the decellularized 3D-scaffold with human stem cells.
- the stem cells are suspended in liquid medium and seeded onto a piece of the decellularized 3D- scaffold, e.g. by use of pipette.
- the stem cells are then incubated and/or centrifuged for some time to allow cell attachment.
- the stem cells may originate from e.g. bone marrow, adipose, or blood.
- the stem cells are subsequently allowed to expand and differentiate in the recellularized 3D-scaffold. Hereby, they need not be expanded and differentiated prior to inoculation.
- the stem cells may be cultured in a bioreactor, e.g. for 4 weeks.
- the osteogenesis medium may be supplemented with heat inactivated human AB serum, L- glutamine, antimycotic-antibiotic, L-Ascorbic acid, b Glycerophosphate, and/or dexamethasone.
- the chondrogenesis medium may be supplemented with heat inactivated human AB serum, L-glutamine, anti-mycotic-antibiotic, bone morphogenetic protein 2 (BMP-2), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-transferrin-selenium (ITS), and/or dexamethasone.
- the recellularized tissue may be characterized by methods known in the art such as histology, immunohistochemistry, and/or by gene expression.
- Fig. 2a and 2b illustrate a flow chart for a method for recellularizing a decellularized 3D-scaffold.
- all human stem cells are inoculated altogether in one portion.
- the number of human stem cells may for example be 1 million.
- the human stem cells may be inoculated on top of the body part.
- the inoculated 3D-scaffold is incubated for 60 min. Then the incubated 3D-scaffold if centrifuged and cultured, for 5 min and cultured for 4 weeks.
- Fig. 2b illustrates a method recellularization wherein the human stem cells are inoculated sequentially.
- the number of human stem cells may be for example 0.2 million and the human stem cells may be inoculated on top.
- the inoculated 3D-scaffold is left for 5 min.
- another portion of 0.2 million cells are inoculated.
- the procedure is repeated for five times.
- the inoculated 3D-scaffold is then centrifuged e.g. for 1 min and thereafter cultured for 4 weeks.
- Fig. 3 illustrates a comparison of an inoculated 3D-scaffold that has been centrifugated and an inoculated 3D-scaffold without centrifugation. Many more human stem cells have been inoculated deeper into the 3D-scaffold with centrifugation compared to no centrifugation.
- the skilled person realizes that a number of modifications of the embodiments described herein are possible without departing from the scope of the disclosure, which is defined in the appended claims. Examples
- tissue biopsies were collected and processed for histology.
- the biopsies were fixed in 4% formaldehyde for 24 hours and dehydrated by standard tissue processing and paraffin embedding. Sections of 5 pm thickness were cut using microtome.
- HE hematoxylin and eosin
- Sterilized tissue pieces were cut into 0.4x0.4x0.1cm in a Petri dish and placed in 6 wells of a 24-well transwell plate. Sterilized tissue was placed in DMEM, supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 % antimitotic-antibiotic over night at 37 ° C incubator.
- the washed tissue pieces were placed on 12-well transwell membrane (0.4 pm pore size) and the MSC isolated human bone marrow, were seeded at approximately 30x106 cells per piece.
- the cells were suspended in 200 pi medium and seeded onto the tissue piece using 10 pi pipette tip and then incubated for an hour to allow cell attachment or centrifuged at 1000 rpm for 5 min. Later, 2 ml medium was added gently along the sides of the well and cultured for 4 weeks in transwell plates in a bioreactor.
- One set of transwells were cultured in osteogenesis medium, while cells in the second set of transwells were cultured in chondrogenesis medium.
- the osteogenesis medium was supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 %, antimycotic-antibiotic, 1 mM L- Ascorbic acid, 10mM b Glycerophosphate, 10nM Dexamethasone.
- the chondrogenesis medium (MEM) was supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 % anti-mycotic-antibiotic, BMP-2, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin- transferrin-selenium (ITS), and dexamethasone.
- Recellularized tissue were performed immunohistochemistry staining.
- the slides were rehydrated, antigen retrieved and endogenous peroxidase blocked by standard procedure.
- Primary antibodies were used for staining included Osteocalcin (1 :50MA), Collagen I (1 :100), DMP-1 (1 :100), RANK (1 :200), CD105 (1 :100), CD 68 (1 :100).
- the sections were incubated with primary antibodies overnight at 4 ° C. Sections were washed with PBS and incubated with secondary antibody (Invitrogen) for 10 min at room temperature. Colorimetric identification was performed using 3, 3 ' -diaminobenzidine and counter-stained with hematoxylin. Decellularized sections were as reference and sections which were absent primary antibody on the same slides were as negative controls.
- RNA from cells cultured in chondrogenesis medium, recellularized marine tissue and a negative control (water) were extracted using Qiagen RNeasy Mini Kit.
- Reverse transcription The 10 extracted samples were reverse transcribed using TATAA GrandScript cDNA Synthesis Kit.
- qPCR The preamplified samples were thawed by adding RNase free water to each sample and mixed. The diluted samples and no-template control (water) were analyzed in duplicates for 20 genes, using same assays as in preamplification, in a Bio-Rad cfx384 Real-Time System and then quantified according to standard methods.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a method for generation of personalized tissue- engineered human grafts. The method comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, the body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing the body part with distilled water; c) decellularizing the washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix (ECM) proteins, and d) recellularizing the decellularized 3D-scaffold by: inoculating human stem cells into the decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in vitro culturing the human stem cells in the inoculated 3D-scaffold.
Description
MARINE SCAFFOLDS FOR HUMAN TISSUE GENERATION
FIELD OF THE INVENTION
The present inventive concept relates to the field of marine scaffold matrices for generation of personalized tissues for future clinical application. More particularly, the inventive concept relates to a method for generation and evaluation of personalized human grafts using decellularized marine invertebrates as novel bio-scaffolds recellularized with patient’s autologous stem cells.
BACKGROUND Osteoarthritis (OA) is a degenerative joint disease that affects millions of people worldwide. The disease is characterized by progressive loss of hyaline cartilage in the synovial joints which leads to significant joint pain, swelling and stiffness for sufferers. The disease is also a significant economic burden. The current gold standard treatment option for OA is total joint arthroplasty where the diseased cartilage and underlying bone are replaced with a metal and polymer prosthesis. While the procedure is well established failures and complications are not uncommon. For tissues such as cartilage the need for new approaches is large since the body’s own capability to produce and heal cartilaginous tissue is poor.
Bone is well known for its self-healing abilities. Nevertheless, in pathological fractures or large and massive bone defects, bone healing and repair fail. Major bone reconstruction procedures often use autografts, allografts, or xenografts to improve bone healing, but these have their disadvantages and limitations.
Advances in tissue engineering have facilitated the development of replacement tissues or organs for the treatment of injured or degenerative tissue. Scaffolds represent important components for tissue engineering. One group of biological scaffold materials that are already commonly in use for a variety of reconstructive surgical applications is that derived from the extracellular matrix (ECM). Such scaffolds are produced by the process of decellularization of tissue/organs.
The rationale behind using native matrix materials is the isolation of ECM proteins that are site-specific and provide protein ‘footprints’ of previous resident cells. ECM derived from decellularization of various organs and tissues such as liver, bladder, blood vessel, lung, bone, etc has shown promising results in creating a biological scaffold capable of providing a favourable environment for survival, proliferation, and differentiation of the resident cells (stem cells/primary cells).
WO201 2/058617 discloses a method for forming a bone tissue module comprising inducing different progenitor cells to form osteogenic progenitor cells, expanding the osteogenic progenitor cells, combining the osteogenic progenitor cells and a scaffold, i.e. decellularized bone and incubating the osteogenic progenitor cells and the scaffold, seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
WO94/03584 discloses a method of producing graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells i.e. a marine animal connective tissues or produced from extracellular matrix proteins; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth to form a processed connective tissue source; and c) fragmenting the processed connective tissue source to produce connective tissue particulates, thereby producing graft tissue, seeding the connective tissue particulates with cultivated cells under such conditions that the cells
adhere to the connective tissue particulates. However, the product obtained by this method is suitable for 3D-printing but is less suitable for direct use since the connective tissue is fragmented into particulates.
So far, research has been focused mainly on decellularizing mammalian scaffolds ignoring diverse opportunities like regenerative ability of marine invertebrates. Marine life and its rich biodiversity provide a plentiful resource of potential new products for the society. Remarkably, marine organisms remain a largely unexploited resource for biotechnology applications. A possible sustainable source of scaffolds could be marine invertebrates, more precisely species with high regenerative capabilities such as starfish. Moreover, these do not have a central nervous system which is why their use does not raise many ethical issues.
CN1 10193096 discloses a marine-derived biomimetic cartilage material and a preparation method thereof. The marine-derived cartilage may derive from fish cartilage, shark cartilage, stingray cartilage, mackerel cartilage, squid cartilage, etc. The method comprises the steps of decellularizing the cartilage for direct use in human bodies. However, the method specifically makes use of cartilage which means the cartilage must be isolated from the remaining part of the marine subject prior to decellularization. Another problem lies in that the product obtained is not adapted for humans and therefore it takes time for the human body to accept it as graft since no human cells are introduced.
Thus, there remains need for improved methods for generation of personalized tissue-engineered human grafts for direct use.
SUMMARY
An object of the disclosure is to provide a method for generation of personalized tissue-engineered human grafts for direct use.
According to a first aspect of the disclosure, these and other objects are achieved, in full or at least in part, by a method for generation of personalized tissue-engineered human grafts, the method comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, the body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing the body part with distilled water; c) decellularizing the washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix (ECM) proteins, and, optionally, d) recellularizing the decellularized 3D-scaffold by: inoculating human stem cells into the decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in vitro culturing the human stem cells in the inoculated 3D-scaffold.
The method provides the advantage that the starting material comprises tissue that is maintained in its natural environment, i.e. the tissues are not separated from each other. Some advantages of using unseparated tissues are presence and accessibility of multitude nutrients which enhances tissue growth. Furthermore, time for separation processes is saved and valuable materia is not cut off. Moreover, it is an advantage to use whole body parts of marine invertebrates since it better resembles human tissue and therefore suits for generation of tissue engineered human grafts for direct use.
According to one example embodiment, a method for generation of personalized tissue-engineered human grafts for direct use, the method comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, the body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing the body part with distilled water;
c) decellularizing the washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix (ECM) proteins, and, d) recellularizing the decellularized 3D-scaffold by: inoculating human stem cells into said decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in vitro culturing said human stem cells in said inoculated 3D-scaffold.
Marine invertebrates Many marine invertebrates have capacity to regenerate their internal and exterior organs and thus constitute suitable scaffolds for tissue engineering. Furthermore, many marine invertebrates possess ECM proteins that are immunologically related to known ECM proteins found in vertebrates, e.g. fibronectin, laminin, fibrillar collagen which has strong similarities with collagen type I, and glycosaminoglycans which belongs to the sulphate family. They also may possess a hyalin layer, an apical lamina, and the basal lamina which is beneficial since it provides a more complex and robust structure. Furthermore, several matrix metalloproteinases and tissue inhibitors of metalloproteinases have been found in marine invertebrates. Marine invertebrates thus constitute a prominent and sustainable source for scaffolds for tissue engineering.
According to one example embodiment, the marine invertebrate is selected from Echinoderms, Poriferans, Cnidarians, Mollusks, or Arthropods; preferably wherein the marine invertebrate is selected from Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies. Non-limiting examples of poriferans are sponges, of Cnidarians are sea Jellies and Corals, of Mollusks are octopuses, snails, and clams, and of Arthropods are insects, spiders, and lobsters. According to one example embodiment, the body part derived from echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, and
sea lilies. Starfish is advantageous since it is possible to derive large body parts therefrom and it contains large amounts of soft tissue and muscle which is easier to recellularize than bony tissue.
According to one example embodiment, the body part derives from Echinoderms, Poriferans, Cnidarians, Mollusks, or Arthropods; or wherein the body part derive from Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies.
For commercialization reasons, it is an advantage if the body part is large enough to produce reasonable amounts of tissue engineered human grafts. Naturally, the larger the body part the more tissue engineered human graft may be obtained. The body part may be at least 5 cm in length, such as at least 10 cm, and preferably at least 20 cm in length.
Decalcification
According to one example embodiment, the method further comprises a step of decalcifying the washed body part obtained in step b) before the step c). Decalcification describes a technique for removing calcium ions and/or other mineral from bone or other calcified tissues in order to soften. Decalcification is thus advantageous in cases of bony and/or hard tissue structures. It is easier to recellularize a decalcified tissue than a non-decalcified tissue since the decalcification makes the tissue softer, especially if the tissue originally comprises substantial amounts of bone.
In one example embodiment, the step of decalcification is employed by a decalcification media comprising an acid, such as hydrochloric acid, nitric acid, and formic acid.
In one example embodiment, the step of decalcification is employed by a decalcification media comprising an acid and a chelating agent.
In one example embodiment, the step of decalcification is employed by a decalcification media comprising a chelating agent. Non-limiting examples of chelating agents are ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), iminodisuccinic acid (IDS), polyaspartic acid, S,S-ethylenediamine- N,N'-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), L-Glutamic acid N,N-diacetic acid, and tetrasodium salt (GLDA).
In one example embodiment, the tissue is shaken during the step of decalcification. The time for shaking may be 2-4 hours.
In one example embodiment, the decalcification is employed at room temperature. Decellularization
Decellularization refers to a process of removal of substantially all cellular components in the tissue. The resulting decellularized 3D-scaffold is substantially depleted of cellular cytoplasmic and nuclear material. Hereby, the decellularized 3D-scaffold may be described as substantially immunologically inert. Decellularization may be employed by physical means and/or decellularization media such as detergents, salts, and enzymes. It is an advantage if the decellularization results in a decellularized 3D-scaffold which is kept as intact and natural as possible. Hereby, recellularization is easier and it is also easier to integrate the human graft in the human body. The decellularization may result in a decellularized 3D-scaffold which comprises muscle, collagen, GAG, signal peptides, and/or growth factors. For this reason, it is advantageous to use soft decellularization media.
In one example embodiment, the decellularized 3D-scaffold has a concentration of DNA of less than 20 ng dsDNA/mg body part (dry weight).
In one example embodiment, the decellularized 3D-scaffold has a fragment length of the DNA of less than 200 bp.
According to one example embodiment, the decellularization media comprises trypsin. Trypsin, which is a commonly used enzyme for tissue decellularization, is classified as a soft decellularization media. Using trypsin, in particular low concentration of trypsin, is advantageous since it results in an intact and natural decellularized 3D-scaffold. The concentration of trypsin may be from 0.01 wt% to 1 wt%, such as from 0.05 wt% to 0. 075 wt%.
According to one example embodiment, the step c) comprises addition of a decellularization media comprising trypsin and a chelating agent. As mentioned above the concentration of trypsin may be between 0.01 wt% to 1 wt%, such as 0.05 wt% to 0. 75 wt%. The concentration of chelating agent may be from 0.1 mM to 20 mM, such as 5 mM to 10 mM.
Non-limiting examples of chelating agents are ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), iminodisuccinic acid (IDS), polyaspartic acid, S,S-ethylenediamine-N,N'-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), L-Glutamic acid N,N-diacetic acid, and tetrasodium salt (GLDA).
In one example embodiment, the decellularization media comprises trypsin and ethylenediaminetetraacetic acid (EDTA). EDTA is often used with trypsin, an enzyme that acts as a protease to cleave the already existing bonds between integral proteins of neighboring cells within a tissue. The EDTA-Trypsin combination is efficient for decellularizing decalcified tissues.
Among the detergents, sodium dodecyl sulfate (SDS) is commonly used for tissue decellularization. However, residual SDS is difficult to completely remove and may lead to an undesirable host response towards an implanted biomaterial.
Furthermore, SDS is classified as a harsh detergent which is effective in cell elimination but causes disturbance of the ECM structure and denaturation of the ECM proteins. SDS may also cause removal of non-fibrillar elements, such as reduced GAGs and growth factor content, as well as denaturation of collagen. Preservation of non-fibrillar elements such as GAG and proteoglycans is advantageous since they play an important role in cell-cell interaction, cell adhesion, survival, migration, proliferation, and maintaining the 3D structure and hydration level of the tissue. Hence, the decellularization media may be a non-SDS based decellularization media. The decellularization may for example be performed by a decellularization media which comprises no more than 2 wt% SDS, no more than 1 wt% SDS, and preferably no SDS.
Another reason why other decellularization media than SDS is preferred is that using decellularization media which contains SDS, or is SDS-based, may cause loss in mechanical properties of the ECM structure, resulting in a decellularized scaffold without 3D-structure. Such decellularized scaffold typically contains only collagen and negligible amounts of GAGs. A way to overcome this problem is to crosslink the ECM structure, i.e. the collagen. However, it is generally more difficult to attach cells to a cross-linked decellurarized 3D-scaffold. The more changes made to the body part, the more difficult it is to recellularize it, i.e. to attach cells thereto.
Other harsh decellularization media comprises hydrochloric acid (HCI) and sodium hydroxide (NaOH). The decellularization may for example be performed by a decellularization media which comprises no more than 1 wt% HCI, no more than 0.5 wt%, and preferably no HCI. The decellularization may for example be performed by a decellularization media which comprises no more than 0.5 wt% NaOH, and preferably no NaOH.
According to one example embodiment, the method is performed without crosslinking, i.e. the method may result in a non-crosslinked decellularized 3D- scaffold. In other words, the decellularized 3D-scaffold may be a non- crosslinked decellularized 3D-scaffold.
For reasons of keeping the recellularized tissue as intact as possible, the method may not contain a step of bleaching. According to one example embodiment, the step c) comprises addition of a decellularization media comprising matrix metalloproteinases (MMP) and a chelating agent. Non-limiting examples of activated matrix metalloproteinases are MMP1 , MMP2, MMP3, MMP7, MMP8, MMP9, MMP11, MMP13, and Membrane type 1 -matrix metalloproteinase (MT1-MMP). The concentration of the MMP may be in the interval of 1-10 pg/ml and preferably 2-5 pg/ml. Activated MMPs may be in the interval from 0.5 pg/ml to 10 pg/ml, such as 1.0 pg/ml to 5 pg/ml.
Metalloproteinases are metalloproteinases that are calcium-dependent zinc- containing endopeptidases. Collectively, these enzymes are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands. MMPs are also thought to play a major role in cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense.
In one example embodiment, the step of decellularizing is performed in a temperature range of 15-37°C.
According to one example embodiment, the method further comprises a step of conditioning the decellularized 3D-scaffold. Conditioning may be employed by MMP-inhibitor such as hydroxymates and/or chelating agent such as carboxylates, thiols, and phosphinyls. Hydroxymates are particularly potent inhibitors of MMPs and other zinc-dependent enzymes, due to their bidentate chelation of the zinc atom.
According to one example embodiment, the method further comprises a step of freezing the decellularized 3D-scaffold obtained in step c). Hereby, the decellularized 3D-scaffold is frozen and thawed before the step of recellularizing. The step of decellularization is preferably employed to a fresh body part, i.e. a body part that has not been frozen. The reason for that is that tissue, particularly tissue proteins, may be destroyed if frozen repeatedly.
Stem cells
According to one example embodiment, the human stem cells are isolated from at least one of human bone marrow, blood, and adipose. Stem cells isolated from blood is advantageous since it does not require any surgical operation to collect.
In one example embodiment said stem cells comprise mesenchymal stem cells (MSC). Mesenchymal stem cells (MSCs) also known as mesenchymal stromal cells or medicinal signaling cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).
In one example embodiment, said human stem cells comprise enriched stem cells such as CD271 and/or CD90 expressing cells. CD271 and CD90 are markers used to identify i.e. mesenchymal stem cells from diverse sources. The official full name of CD271 is nerve growth factor receptor (TNFR superfamily, member 16). CD271, also called the LNGFR or p75 neurotrophin receptor, regulates neuronal growth, migration, differentiation, and cell death during stem cells. It is one of the two receptor types for the neurotrophins, a family of protein growth factors that stimulate neuronal cells to survive and differentiate. LNGFR is a member of the tumor necrosis factor receptor (TNF receptor) superfamily.
The official full name of CD90 is Thy-1 cell surface antigen. This gene encodes a cell surface glycoprotein and member of the immunoglobulin superfamily of proteins. The encoded protein is involved in cell adhesion and cell communication in numerous cell types, but particularly in cells of the immune and nervous systems. The encoded protein is widely used as a marker for hematopoietic stem cells.
According to one example embodiment, the human stem cells comprise unexpanded and undifferentiated human stem cells. The human stem cells may then differentiate in the recellularized 3D-scaffold to chondrocytes and/or osteocytes. Chondrocytes are the only cells found in healthy cartilage. They produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans. An osteocyte is an oblate shaped type of bone cell with dendritic processes and is the most commonly found cell in mature bone tissue.
According to one example embodiment, a growth factor is inoculated together with the human stem cells into the decellularized 3D-scaffold
According to one example embodiment, the growth factor comprises chondrogenesis media and/or osteogenesis media.
According to one example embodiment, a growth factor is inoculated together with the human stem cells into said decellularized 3D-scaffold and wherein the growth factor comprises chondrogenesis media and/or osteogenesis media. Non-limiting examples of chondrogenesis medium and their concentrations include: MEM with alpha modification, 1% Penicillin & Streptomycin, 10% inactivated AB serum, 1% L-glutamine, TGF Beta 3 (10 ng/ml), Bone morphogenetic protein-2 (10 ng/ml), Bone morphogenetic protein-4 (10 ng/ml), Basic Fibroblast growth factor (10 ng/ml), Epidermal growth factor (1 ng/ml), Insulin-like growth factor (5 ug/ml), Transferrin (5 ug/ml), Sodium-Selenite (5 ug/ml), Proline (0.35 mM), Ascorbic acid-2-phosphate (0.17 mM) or L-
Ascorbic acid (50 ug/ml), and Dexamethasone (100nM). Non-limiting examples of Osteogenesis medium and their concentrations include: Minimum essential medium (MEM) (High glucose), Penicillin & Streptomycin, 10% inactivated AB serum, 1 % L-glutamine, L-Ascorbic acid (1 mM), Beta-Glycerophosphate (10 mM), and Dexamethasone (10 nM).
Inoculation and Centrifugation
Cell attachment to a scaffold is a significant step toward successful tissue engineering. Cell inoculation is the first stage of cell attachment, and its efficiency and distribution can affect the final biological performance of the scaffold.
Efficiency in this context may be defined as seeding efficiency of at least 40% of seeded cells as determined by the quantity of cellular DNA within 5 hours after seeding.
Distribution in this context may be defined as percentage of area occupied by cells in tissue as enumerated and quantified by histology.
The cells may be inoculated by seeding, such as by injection or perfusion.
According to one example embodiment, the step d) further comprises centrifugating the inoculated 3D-scaffold. Centrifugation is advantageous since it may improve cell distribution within the body part. Centrifugation may also decrease the time for cell attachment. The centrifugation may be performed during at least 1 minute, at least 3 minutes or at least 5 minutes.
In one example embodiment at least 0.1 million cells/mm2, at least 0.2 million cells/mm2, at least 0.3 million cells /mm2, at least 0.4 million cells/mm2, or at least 0.5 million cells/mm2 are seeded to the decellularized 3D-scaffold. In one example embodiment, 1 million cells/mm2 are inoculated to the decellularized
3D-scaffold. The cells may be inoculated all at the same time or portion-wise in intervals. The cells may be inoculated on top of the decellularized 3D-scaffold.
In one example embodiment, the inoculated decellularized 3D-scaffold is centrifugated directly after inoculation. In one example embodiment, the inoculated 3D-scaffold is centrifugated at least 5 min, at least 15 min, at least 30 min, at least 45 min or at least 60 min after seeding.
Culturing
In one example embodiment, the step of recellularizing further comprises culturing of cells in a bioreactor for 1-8 weeks, and preferably 2-4 weeks. A result of this is that the cultured cells express human genes.
Product
According to a second aspect of the disclosure, a tissue-engineered human graft as herein described is provided.
In one example embodiment, the tissue-engineered human graft may express human genes. The detection of human genes may be performed by Real-Time polymerase chain reaction (PCR), microarray or by Proteomics.
According to one example embodiment, the graft comprises soft bone and/or cartilage. Soft bone is also called cancellous trabecular or spongy bone. It consists of a network of trabeculae or rod-like structures. It is lighter, less dense, and more flexible than compact bone. Soft bone is a very porous type of bone found in animals. It is highly vascularized and contains red bone marrow. Soft bone is usually located at the ends of the long bones, with the harder compact bone surrounding it. It is also found inside the vertebrae, in the ribs, in the skull and in the bones of the joints. Soft bone is softer and weaker than compact bone but is also more flexible. It is characterized by a lattice-like
matrix network called trabeculae that gives it its spongy appearance. Compact (cortical) bone is a hard outer layer that is dense, strong, and durable. It makes up around 80 percent of adult bone mass.
According to one example embodiment, the tissue-engineered human graft as herein described comprises soft bone, cartilage, and/or skin. Further examples of tissue-engineered human grafts obtainable by the invention are skin and blood vessels.
According to one example embodiment, a tissue engineered human graft for use in therapy is provided.
According to one example embodiment, a tissue engineered human graft for treatment of Osteoarthritis is provided.
According to one example embodiment, a tissue engineered human graft for treatment of joint diseases is provided. Non-limiting examples of joint diseases are Osteoarthritis, Post-traumatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Osteoporosis, Discoid meniscus, Bone disorders such as Bone Cancer, Bone Density, Bone Infections, Osteogenesis Imperfecta, Osteonecrosis, Osteoporosis, Paget's Disease of Bone, and Rickets.
According to one example embodiment, a tissue engineered human graft as herein described may be used as ink for 3D printing. The ink is provided with good mechanical properties. It is an advantage if the ink comprises muscle because this gives stiffness to the printed material. Collagen, GAGs, signal peptides, and/or growth factors further enhance stiffness and allow the cells to adhere to the ink in an efficient way. The ink may comprise polysaccharides such as mannoglucan sulfate, P1 and P2 which act as antioxidants and enhance cell adhesion, migration, and differentiation. The ink exhibits good printability and mechanical properties needed for 3D microgeometry integrity and required cellular functions such as viability and differentiation.
Definitions
Generally, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to “a/an/the [element, device, component, means, step, etc.]” are to be interpreted openly as referring to at least one instance of the element, device, component, means, step, etc., unless explicitly stated otherwise. The steps of any method disclosed herein do not have to be performed in the exact order disclosed, unless explicitly stated. Decellularization refers to the process of removal of substantially all cellular components in a tissues/organ by physical, chemical and/or enzymatic methods.
Recellularization refers to the process of delivering cells to a decellularized 3D- scaffold and culturing the cells such that the cells proliferate and differentiate to generate a personalized tissue-engineered human graft.
Decalcification describes the technique for removing calcium ions and/or other mineral from bone or other calcified tissues to soften.
Autologous stands for obtained from the same individual.
Inoculation refers to the spread of cells to a tissue or body part for cell culture activities.
BRIEF DESCRIPTION OF THE DRAWINGS
The disclosure will be described in more detail with reference to the appended schematic drawings, which show an example of a presently preferred embodiment of the disclosure.
Fig. 1 illustrates a flow chart for a method for generation of personalized tissue- engineered human grafts for direct use according to at least one example embodiment of the inventive concept;
Fig. 2a illustrates a flow chart for a method for recellularization of a decellularized 3D-scaffold according to at least one example embodiment of the inventive concept;
Fig. 2b illustrates a flow chart for a method for recellularization of a decellularized 3D-scaffold;
Fig. 3a and 3b illustrate a comparison of an inoculated 3D-scaffold without centrifugation and an inoculated 3D-scaffold with centrifugation.
DETAILED DESCRIPTION
The present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which currently preferred embodiments of the disclosure are shown. The present disclosure may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided for thoroughness and completeness, and to fully convey the scope of the disclosure to the skilled addressee. Like reference characters refer to like elements throughout.
Fig. 1 illustrates a flow chart for a method for generation of personalized tissue- engineered human grafts for direct use. First, a body part taken from marine invertebrates is collected and washed with distilled water to remove debris. Possibly the body part is maintained in flowing sea water until needed.
In cases of bony or hard structures, the body part is preferably decalcified in order to make it softer. Non-limiting examples of decalcification media are
hydrochloric acid, nitric acid, formic acid, and ethylenediaminetetraacetic acid (EDTA). Optionally, the body part is subjected to stirring during decalcifying. The time for decalcification may be two hours and the temperature may be room temperature. Subsequently the decalcified body part is preferably repeatedly washed with distilled water.
Next, the body part is decellularized into a decellularized 3D-scaffold which means substantially all cells and DNA are removed. Decellularization is preferably also performed during stirring. The time for decellularization may be two hours and the temperature may be 37 °C. Non-limiting examples of decellularization media are trypsin-EDTA. The outcome of decalcification and decellularization processes may be analyzed by histology.
The decellularized 3D-scaffold may now be frozen until later use. Hereby, an off-the-shell product is produced.
Before the decellularized 3D-scaffold is recellularized, it is preferably is sterilized and conditioned. Sterilization may be performed by subjecting the 3D- scaffold to peracetic acid in sterile phosphate-buffered saline (PBS) for 1 hour on a shaker at room temperature. Bony tissue may be washed with sterile PBS three times, each time for 20 minutes.
Recellularization is performed by inoculating, such as seeding, the decellularized 3D-scaffold with human stem cells. Preferably the stem cells are suspended in liquid medium and seeded onto a piece of the decellularized 3D- scaffold, e.g. by use of pipette. The stem cells are then incubated and/or centrifuged for some time to allow cell attachment. The stem cells may originate from e.g. bone marrow, adipose, or blood. The stem cells are subsequently allowed to expand and differentiate in the recellularized 3D-scaffold. Hereby, they need not be expanded and differentiated prior to inoculation. The stem cells may be cultured in a bioreactor, e.g. for 4 weeks. Growth factors for this include osteogenesis media and/or chondrogenesis media. The osteogenesis medium may be supplemented with heat inactivated human AB serum, L-
glutamine, antimycotic-antibiotic, L-Ascorbic acid, b Glycerophosphate, and/or dexamethasone. The chondrogenesis medium may be supplemented with heat inactivated human AB serum, L-glutamine, anti-mycotic-antibiotic, bone morphogenetic protein 2 (BMP-2), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-transferrin-selenium (ITS), and/or dexamethasone.
In order to control the outcome of the recellularization the recellularized tissue may be characterized by methods known in the art such as histology, immunohistochemistry, and/or by gene expression.
Fig. 2a and 2b illustrate a flow chart for a method for recellularizing a decellularized 3D-scaffold. In Fig. 2a all human stem cells are inoculated altogether in one portion. The number of human stem cells may for example be 1 million. The human stem cells may be inoculated on top of the body part. After inoculation the inoculated 3D-scaffold is incubated for 60 min. Then the incubated 3D-scaffold if centrifuged and cultured, for 5 min and cultured for 4 weeks.
Fig. 2b illustrates a method recellularization wherein the human stem cells are inoculated sequentially. The number of human stem cells may be for example 0.2 million and the human stem cells may be inoculated on top. After the inoculation, the inoculated 3D-scaffold is left for 5 min. Then another portion of 0.2 million cells are inoculated. The procedure is repeated for five times. The inoculated 3D-scaffold is then centrifuged e.g. for 1 min and thereafter cultured for 4 weeks.
Fig. 3 illustrates a comparison of an inoculated 3D-scaffold that has been centrifugated and an inoculated 3D-scaffold without centrifugation. Many more human stem cells have been inoculated deeper into the 3D-scaffold with centrifugation compared to no centrifugation.
The skilled person realizes that a number of modifications of the embodiments described herein are possible without departing from the scope of the disclosure, which is defined in the appended claims. Examples
Materials and methods
Viable starfishes (n=10) kept in aquaculture water were transported to lab. All arms were removed from an individual initially possessing five arms and were cleaned thoroughly with distilled water.
Decalcification and decellularization of starfish bony tissue The tissue (5x0.8x0.2 cm) was decalcified in 1 N hydrochloric acid on a shaker (rpm= 240) for 2 hours at room temperature and washed with distilled water for three times (3x20 min) under the same shaking condition. After washing, the tissue was decellularized with 0.05% of trypsin-EDTA on a shaker (rpm= 70) for 2 hours at 37°C. Bony tissue was washed with distilled water for three times (3x20 min) with the same rpm on shaker at room temperature. Decellularized bony tissue was then sterilized. Decellularized starfish bony tissue pieces were sterilized in 0.1 % of peracetic acid in sterile PBS for 1 hour on a shaker (rpm= 240) at room temperature. Bony tissue was washed with sterile PBS three times, each time for 20 minutes.
Characterization of decellularized starfish bony tissue
After decalcification and decellularization, tissue biopsies were collected and processed for histology. The biopsies were fixed in 4% formaldehyde for 24 hours and dehydrated by standard tissue processing and paraffin embedding. Sections of 5 pm thickness were cut using microtome. After series steps of rehydration hematoxylin and eosin (HE) staining were performed. Decalcified slides were as a control and 4', 6-diamino-2 phenylindole staining were also performed to confirm the HE findings.
Conditioning of decellularized bone tissue
Sterilized tissue pieces were cut into 0.4x0.4x0.1cm in a Petri dish and placed in 6 wells of a 24-well transwell plate. Sterilized tissue was placed in DMEM, supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 % antimitotic-antibiotic over night at 37°C incubator.
Recellularization of starfish bone - Seeding of decellularized starfish bony tissue with BM-MSC
The washed tissue pieces were placed on 12-well transwell membrane (0.4 pm pore size) and the MSC isolated human bone marrow, were seeded at approximately 30x106 cells per piece. The cells were suspended in 200 pi medium and seeded onto the tissue piece using 10 pi pipette tip and then incubated for an hour to allow cell attachment or centrifuged at 1000 rpm for 5 min. Later, 2 ml medium was added gently along the sides of the well and cultured for 4 weeks in transwell plates in a bioreactor. One set of transwells were cultured in osteogenesis medium, while cells in the second set of transwells were cultured in chondrogenesis medium.
The osteogenesis medium was supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 %, antimycotic-antibiotic, 1 mM L- Ascorbic acid, 10mM b Glycerophosphate, 10nM Dexamethasone. The chondrogenesis medium (MEM) was supplemented with 10% heat inactivated human AB serum, 1 % L-glutamine, 1 % anti-mycotic-antibiotic, BMP-2, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin- transferrin-selenium (ITS), and dexamethasone.
Characterization of recell ularized 3D-scaffold 1 ) Histology
By end of recellularization biopsies from each chamber were collected and fixed in 4% formaldehyde for 24 hours. Samples were dehydrated with ascending concentrations of ethanol, and Xtrasolv by tissue processor and
embedded in paraffin. The paraffin blocks were sectioned at 5um thickness and stained with hematoxylin and eosin (HE). Simultaneously 4', 6-diamino-2 phenylindole (DAPI) staining were also performed to conform the HE findings.
2) Immunohistochemistry
Recellularized tissue were performed immunohistochemistry staining. The slides were rehydrated, antigen retrieved and endogenous peroxidase blocked by standard procedure. Primary antibodies were used for staining included Osteocalcin (1 :50MA), Collagen I (1 :100), DMP-1 (1 :100), RANK (1 :200), CD105 (1 :100), CD 68 (1 :100). The sections were incubated with primary antibodies overnight at 4°C. Sections were washed with PBS and incubated with secondary antibody (Invitrogen) for 10 min at room temperature. Colorimetric identification was performed using 3, 3'-diaminobenzidine and counter-stained with hematoxylin. Decellularized sections were as reference and sections which were absent primary antibody on the same slides were as negative controls.
3) Detection of human genes in the cultured 3D-scaffold
RNA from cells cultured in chondrogenesis medium, recellularized marine tissue and a negative control (water) were extracted using Qiagen RNeasy Mini Kit.
Reverse transcription: The 10 extracted samples were reverse transcribed using TATAA GrandScript cDNA Synthesis Kit. qPCR: The preamplified samples were thawed by adding RNase free water to each sample and mixed. The diluted samples and no-template control (water) were analyzed in duplicates for 20 genes, using same assays as in preamplification, in a Bio-Rad cfx384 Real-Time System and then quantified according to standard methods.
Claims
1. A method for generation of personalized tissue-engineered human grafts, said method comprising the following steps in the order named: a) providing a body part taken from a marine invertebrate, said body part comprising at least two biologically interconnected tissues selected from the group consisting of connective tissue, muscle tissue, epithelia tissue, and nervous system tissue; b) washing said body part with distilled water; c) decellularizing said washed body part to remove cells and DNA, to provide a decellularized 3D-scaffold with extracellular matrix, ECM, proteins, and d) recellularizing said decellularized 3D-scaffold by: inoculating human stem cells into said decellularized 3D-scaffold thus obtaining an inoculated 3D-scaffold, and in vitro culturing said human stem cells in said inoculated 3D-scaffold.
2. The method according to claim 1 , wherein said human stem cells are isolated from at least one of bone marrow, blood, and adipose.
3. The method according to claim 1 or 2, wherein said human stem cells comprise enriched human stem cells such as CD271 and/or CD90 expressing cells.
4. The method according to any one of claims 1-3, wherein said step d) further comprises centrifugating said inoculated 3D-scaffold.
5. The method according to any one of claims 1-4, wherein said human stem cells in said inoculated 3D-scaffold is cultured in a bioreactor for 1-8 weeks, and preferably 2-4 weeks.
6. The method according to any one of claims 1 -5, wherein a growth factor is inoculated together with the human stem cells into said decellularized 3D- scaffold and wherein said growth factor comprises chondrogenesis media and/or osteogenesis media.
7. The method according to any one of claims 1-6, further comprising a step of decalcifying said washed body part obtained in step b) before said step c).
8. The method according to any one of claims 1-7, wherein said step c) comprises addition of a decellularization media comprising trypsin and a chelating agent.
9. The method according to any one of claims 1-7, said step c) comprises addition of a decellularization media comprising activated matrix metalloproteinases, MMP, and a chelating agent.
10. The method according to any one of claims 1-9, wherein said marine invertebrate is selected from Echinoderms, Poriferans, Cnidarians, Mollusks, or Arthropods; preferably wherein said marine invertebrate is selected from Echinoderms such as starfish, sea urchins, sand dollars, sea cucumbers, or sea lilies.
11. The method according to any one of claims 1-10, further comprising a step of freezing said decellularized 3D-scaffold obtained in step c).
12. A tissue-engineered human graft obtained by the method according any one of claims 1-11.
13. The tissue engineered human graft according to claim 12, wherein said graft comprises soft bone and/or cartilage.
14. The tissue engineered human graft according to claim 12 or 13, for use in therapy.
15. The tissue engineered human graft according to any one of claims 12- 14, for use as ink for 3D printing.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21167738.0A EP4070824A1 (en) | 2021-04-09 | 2021-04-09 | Marine scaffolds for human tissue generation |
PCT/EP2022/059530 WO2022214693A1 (en) | 2021-04-09 | 2022-04-08 | Marine scaffolds for human tissue generation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4319827A1 true EP4319827A1 (en) | 2024-02-14 |
Family
ID=75441851
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21167738.0A Withdrawn EP4070824A1 (en) | 2021-04-09 | 2021-04-09 | Marine scaffolds for human tissue generation |
EP22721770.0A Pending EP4319827A1 (en) | 2021-04-09 | 2022-04-08 | Marine scaffolds for human tissue generation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21167738.0A Withdrawn EP4070824A1 (en) | 2021-04-09 | 2021-04-09 | Marine scaffolds for human tissue generation |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP4070824A1 (en) |
WO (1) | WO2022214693A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7304665B1 (en) * | 2023-04-06 | 2023-07-12 | リージョナルフィッシュ株式会社 | Method for decalcifying shell of individual shellfish, method for observing individual shellfish, and demineralization solution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2141851A1 (en) | 1992-08-07 | 1994-02-17 | Eugene Bell | Production of graft tissue from extracellular matrix |
SI2367556T1 (en) * | 2008-11-20 | 2019-09-30 | Cartiheal (2009) Ltd. | Solid forms for tissue repair |
US20140147419A1 (en) | 2010-10-29 | 2014-05-29 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for formation of bone tissue |
CN110193096A (en) | 2019-05-29 | 2019-09-03 | 上海市第六人民医院 | A kind of marine origin biomimetic type cartilage material and preparation method thereof |
-
2021
- 2021-04-09 EP EP21167738.0A patent/EP4070824A1/en not_active Withdrawn
-
2022
- 2022-04-08 EP EP22721770.0A patent/EP4319827A1/en active Pending
- 2022-04-08 WO PCT/EP2022/059530 patent/WO2022214693A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022214693A1 (en) | 2022-10-13 |
EP4070824A1 (en) | 2022-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5919702A (en) | Production of cartilage tissue using cells isolated from Wharton's jelly | |
Schumann et al. | Treatment of human mesenchymal stem cells with pulsed low intensity ultrasound enhances the chondrogenic phenotype in vitro | |
JP6875297B2 (en) | Bone-forming graft formation unit | |
Caplan | Adult mesenchymal stem cells for tissue engineering versus regenerative medicine | |
US7863045B2 (en) | Isolation of skeletal precursor cells | |
EP2970882B1 (en) | Cell repopulated collagen matrix for soft tissue repair and regeneration | |
US20160067377A1 (en) | Stem Cell Seeded Natural Substrates and Methods Relating Thereto | |
US20120276203A1 (en) | Collagen matrix for cell therapy | |
KR101178153B1 (en) | New stem cell lines, their application and culture methods | |
CN103223194A (en) | Cartilage graft for cartilage injury repair and preparation method thereof | |
JP6120428B2 (en) | Differentiation-inducing composition | |
WO2022214693A1 (en) | Marine scaffolds for human tissue generation | |
CA3112846A1 (en) | Biomaterial comprising adipose-derived stem cells and gelatin and method for producing the same | |
Chen et al. | Synergetic effects of hBMSCs and hPCs in osteogenic differentiation and their capacity in the repair of critical-sized femoral condyle defects | |
US20030215426A1 (en) | Redifferentiated cells for repairing cartilage defects | |
US11471562B2 (en) | Cartilage material having minimal hypertrophy and robust integration capacity, and uses therefor | |
JP2019510823A (en) | Bone marrow stromal cell-derived extracellular matrix protein extract and use thereof | |
KR101539822B1 (en) | Method for preparing concentrated cell culture medium via 3D-culture and use thereof | |
JP5373427B2 (en) | Use of synovial cells and minced cartilage fragments in cartilage repair | |
Dnyaneshwarrao | DEVELOPMENT, OPTIMIZATION AND BIOLOGICAL EVALUATION OF AMNIOTIC MEMBRANE FOR REGENERATIVE THERAPY | |
Lingling et al. | Recombinant human bone morphogenetic protein-7 enhances bone formation ability of jaw bone defect using human umbilical cord mesenchymal stem cells combined with nano-hydroxyapatite/collagen/poly (L-lactide) | |
CN116212114A (en) | Preparation method of decalcified bone matrix | |
Kim et al. | ENHANCEMENT OF TENDON HEALING USING BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN ROTATOR CUFF TEAR OF A RABBIT MODEL | |
Vitro | Cartilage Repair Skeletal Tissue Stem Cells in TE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230830 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |